Atherosclerosis is the precedent to ischemic heart disease, which may lead to angina, myocardial infarct, or heart failure; or to ischemic cerebrovascular disease, which may lead to stroke. The prevailing belief underlying conventional approaches to treatment of atherosclerosis and its sequel is that a diet high in cholesterol and saturated fat is the main contributory factor, triggering cholesterol build up in the intima of the blood vessels. Over the last 60 years, the blame has shifted from fats, to saturated fats, to low-density lipoprotein (LDL), and finally to oxidized LDL (Ox-LDL). Therapy has been predominantly aimed at lowering cholesterol and control of risk factors. However, there is an alternative hypothesis about the cause of heart disease linking it to the weakening of the vascular collagen matrix at the sites of high hemodynamic stress (coronary arteries) which triggers the infiltration of lipoprotein(apo) [Lp(a)] and plaque development. Accordingly, the vascular deposition of large molecules such as Lp(a) and atherosclerosis is the result of the body's endogenous protective mechanism to reinforce the weakened artery walls. Understanding this mechanism may guide the natural prevention of this disease and form the basis for developing effective therapeutic strategies aiming at natural reversal of atherosclerosis through the reinforcement of the vascular wall structure as its primary goal. This reappraisal of atherosclerosis and the cholesterol theory looked at the historical development of the theory, and the Rath and Pauling unified theory of cardiovascular disease.
plaque buildup around the artery wall. Over time, this occlusion limits flow of oxygenrich blood to the heart. Atherosclerosis is the precedent to coronary heart disease (CHD), which may lead to angina, myocardial infarct, or heart failure; or to ischemic cerebrovascular disease, which may lead to stroke. The prevailing belief underlying conventional approaches to treatment of atherosclerosis and its sequel is that a diet high in cholesterol and saturated fat is the main contributory factor, triggering cholesterol build up in the intima of the blood vessels.
The cholesterol theory in relation to atherosclerosis, or more specifically referred to as the lipid hypothesis, postulates that hypercholesterolemia is a major causative factor, or determining factor, in atherosclerosis and CHD; and correcting it will significantly reduce the burden of disease and its clinical consequences [1] . The hypothesis relates to serum lipids, and not dietary lipids. In the open debate over the last few decades on the role of cholesterol and CHD, the line between serum lipids and dietary lipids is narrow, and the two often merged. This is due to the understanding that consuming high dietary lipids will raise the cholesterol level in the blood. For over half a century, the World Health Organization (WHO) and most countries in the world have been advising a low fat diet. Two other hypotheses emerged in search for a pathogenesis of atherosclerosis, namely the respond-to-injury hypothesis [2] , and the monoclonal hypothesis [3] . However, for both these hypotheses the mechanism leading to the disease is not well explained.
Based on epidemiological evidence at the time, the USA and UK in 1977 and 1983 respectively, issued dietary fat guideline focusing on reducing dietary fat intake to address the incidence of CHD. A recent published systematic review and meta-analysis study showed that the dietary fat guideline issued by the two countries was not based on evidence from randomized controlled trials (RCTs) [4] . There was RCTs evidence available at the time that showed no significant relationship between dietary interventions and CHD and all-cause mortality. The dietary committees of both countries did not consider that evidence.
Considering that heart disease has been the global leading cause of death the last twenty-five years, and will still be by 2030 [5] , a few pertinent questions need be asked: This reappraisal of atherosclerosis and the cholesterol theory looked at the historical development of the theory, and the Rath and Pauling unified theory of cardiovascular disease, to attempt to answer the questions above.
Background

Early Discovery of Cholesterol
The lipid hypothesis of atherosclerosis has its beginning in 1913 when a young Russian experimental pathologist, Nikolai N. Anichkov, showed that feeding rabbits purified cholesterol dissolved in sunflower oil induced vascular lesions [6] . But it was Felix Marchand who first introduced the term "atherosclerosis" in 1904 [7] . Anichkov's study on atherosclerosis was largely unknown in the west. The first publication of Anichkov's theory of atherosclerosis in English medical literature was in Cowdry's Arteriosclerosis [8] . In 1950, when Dr. John Gofman published his paper in Science [9] and cited Anichkov's work, Anichkov began to receive worldwide recognition. Gofman and associates used an ultra-centrifugal device that, at a rotor speed of 52,640 rpm could separate cholesterol basically into two types, low-density lipoprotein and highdensity lipoprotein. Gofman went on to initiate multicenter study of lipoproteins in human plasma and made correlations with atherosclerosis. From then on there was a flood of studies on lipoproteins in relation to atherosclerosis. These studies mainly concentrated on LDL in blood vessel tissues.
Smith and Slater [10] measured LDL in arterial walls and compared these with serum cholesterol levels to show a close relation between LDL cholesterol and atherosclerosis.
A subsequent study [11] confirmed the findings of Smith and Slater [10] . The association between cholesterol and atherosclerosis has been firmly established, and LDL is widely perceived as the causative factor. However, with the mechanism of how the cholesterol molecules get into the walls of blood vessels still unknown, skepticism is inevitable.
From LDL to Oxidized LDL (OxLDL) Hypothesis
The study of familial hypercholesterolemia led Goldstein and Brown to elucidate that the cellular uptake of LDL requires the LDL receptor [12] . Their discovery of the LDL receptor, and later their discovery of the scavenger receptor in macrophage, helped contribute significantly to the lipid theory of atherosclerosis. In 1979 Goldstein and Brown, and their associates, pursued the study of macrophages and LDL. The finding was that macrophages in culture take up and degrade LDL, and that the macrophagederived foam cells accumulate in the artery walls [13] . Another laboratory study [14] took this further discovering that LDL incubated overnight with cultured endothelial cells was converted to a form. Henriksen et al. suggested that LDL modification in endothelium permits LDL uptake and foam cell formation. Follow up studies by others showed that LDL was undergoing oxidative modification during its incubation with endothelial cells [15] [16] . Hence, the beginning of the oxidative modification hypothesis of atherosclerosis, and from thenceforth thousands of studies on atherosclerosis were conducted.
Early Epidemiological Studies
The "lipid theory" or the "fat causes atherosclerosis" theory was developed largely through epidemiological studies. In the 1950's Ancel Keys postulated that fat causes heart disease. It started in 1951 when Keys observed the diet of the people of Naples, Italy, whose diet was low in meat and high in vegetables, and had low rate of CHD [17] .
Keys' thesis was the result of his study of the selection of six countries from which he drew correlation between mortality from CHD and fat consumption [18] . In another study several years later, called the "Seven Countries" study, Keys redefined the fat dietary intake association with CHD, to saturated fat [19] . From then on the blame was on saturated fat and not just any fat.
Atherosclerosis was originally considered to be an ongoing process and a normal part of aging [20] . This perception was checked when a necropsy study was conducted on soldiers killed during the Korean War [21] . In this observational study, Enos and the group [21] described coronary lesions from the autopsies of 300 male soldiers, with a mean age of 22 years, and observed that 77% had coronary disease. The Korean War study was later corroborated by the Vietnam War study [22] 
The Risk Factor Paradigm of CHD
In the absence of any interventional, randomized, controlled trial, the cause of CHD cannot be conclusively determined. So far, the body of evidence accumulated from animal models and epidemiological studies that set out to test the lipid hypothesis have been predominantly observational. The lipid hypothesis proposed that hypercholesterolemia was a causative factor in human atherosclerosis. It did not propose that hypercholesterolemia was the only cause but that it was at least a quantitatively significant factor [1] . The observational studies identified risk factors associated with CHD. Risk factors significantly associated with CHD are smoking, blood lipids, hypertension, diabetes, abdominal obesity, psychosocial factors, fruit and vegetable consumption, alcohol consumption and physical activity [23] . Treatment of CHD has been based on lowering the risk factors. To this date, it has been the established paradigm for the treatment of CHD.
Description
Clinical Trials with Antioxidants
The accumulated evidence that oxidative modification of LDL plays an important role in the pathogenesis of atherosclerosis in animal models is very strong [24] . The evidence arises mostly from cell culture and in vitro settings. Until and unless the OxLDL effect of atherosclerosis is evaluated in live animals, the findings remain suggestive.
Without an understanding of the primary cause of atherosclerosis, the therapeutic approach of lowering the risk factors is not specific. Even the overall result of the 1984
Coronary Primary Prevention Trial using the drug, Cholestyramine, though statistically significant, was not totally convincing [25] .
Over the last fifteen years, several clinical trials have set out to investigate the OxLDL hypothesis of atherosclerosis using antioxidants. The antioxidants used were mainly either vitamin E or beta-carotene. The results have been mixed. There are studies that show antioxidants have no positive effect [26] [27] [28] . A meta-analysis of seven randomized trials of vitamin E treatment and eight of beta-carotene treatment also show that antioxidants do not provide benefit [29] . On the other hand, there are also studies that show beneficial effect of antioxidants on atherosclerosis [30] [31] [32] [33] . These studies differ in their designs with regards to the type of nutrient, dosage, single or two nutrients combination, natural or synthetic form, length of study, study end points, subject population and age group, and the chronicity of the disease (whether pre or post myocardial infarction). In large-scale clinical trials, it is difficult to replicate the exact study design. Therefore, such variation, diverse, and even contradictory results in the studies mentioned above, is quite understandable.
The Vitamin C-Heart Disease Connection
At the time when the study of atherosclerosis was much dependent on autopsy, and when conventional explanation of heart disease was that lipids or cholesterol build up on the surface of arterial walls, Canadian pathologist, J.C. Paterson was studying atherosclerosis and intimal capillary rupture leading to stroke. He suggested that the factors responsible for the rupture of intimal capillaries in the cerebral arteries are intra-capillary pressure from hypertension, degeneration of tissues, and increased capillary fragility due to advancing age and vitamin deficiency [34] . A follow up study by Paterson was conducted on coronary occlusion using microscopic examinations on plaques. It led him to conclude that hypertension is a major factor for intimal capillary bleeding and plaque formation; that capillary fragility may be due to vitamin C deficiency; and that calcification of atherosclerotic plaques may protect against intimal hemorrhages and coronary thrombosis [35] .
The observational studies of Paterson were followed-up by another Canadian, Dr.
G.C. Willis. He conducted an experimental study on guinea pigs and confirmed Paterson's suggestion that atherosclerosis is linked to vitamin C deficiency [36] . Willis also pointed out that the mechanical stress exerted onto the walls of arteries is important in the location of atherosclerosis. This mechanical stress is influenced by blood pressure, surrounding tissue pressure, radius of lumen, curvature of artery, and arterial fixation.
In a later study, Willis [37] showed that vitamin C could reverse atherosclerosis in guinea pigs. In 1954, Willis conducted a controlled clinical study on the development of atherosclerosis in humans examining the femoral and popliteal arteries. Those in the treated group were given 500 mg of vitamin C orally, three times a day, a total of 1500 mg a day. This preliminary serial angiography study showed that vitamin C could reduce atherosclerotic plaques in humans [38] . It was the first time that the evolution of atheromatous plaques had been observed over a period of time. In contrast to previous assumptions, atherosclerosis is not a slow and inevitable progressive disease. Willis' serial angiographic study showed that plaques might enlarge or become smaller fairly quickly. The study also showed that sclerotic build up is not evenly distributed throughout the blood vessels, but at specific points where the mechanical stress exerted most onto the blood vessels.
In 1971, a British pathologist, Dr. Constance Spittle, conducted a study on healthy individuals and patients with atherosclerosis using vitamin C. In healthy people under 25 years, cholesterol levels tended to fall when 1000 mg of vitamin C daily was added to a normal diet whereas, in patients with a history of atherosclerosis, the serum cholesterol increased in the weeks when vitamin C was given. It was suggested that the transitory rise in serum cholesterol is caused by the mobilization from the artery walls [39] .
HMG-CoA reductase is the enzyme in the pathway for cholesterol biosynthesis in the liver. This is the enzyme inhibited by statins [25] . In the early 1980s, among the pharmaceutical companies, there was a strong quest to produce the first drug that could inhibit cholesterol biosynthesis. Merck took the lead and its lovastatin (Mevacor) has
shown promising results in lowering serum cholesterol. It was not until 1987 that the FDA approved lovastatin as a cholesterol-lowering drug. During the same period, Holloway, Peterson, Prigge, and Gebhard [40] observed that cholesterol synthesis in the liver of guinea pigs was reduced when fed with a diet high in vitamin C. The decreased cholesterol synthesis was also associated with the decrease in the fraction of active HMG-CoA reductase. In 1985 Greene, Harwood and Stacpoole followed up on the observation of Holloway et al. to examine the mechanism of inhibition of HMG-CoA reductase activity by vitamin C in guinea pig liver [41] . Their study showed that vitamin C has an effect on the reductase activity and cholesterol genesis. Greene and colleagues followed up on their own study and advanced from animal model studies to the study of cultured human liver cells and mononuclear leukocytes. The findings were that low-level vitamin C triggers the enzyme HMG-CoA reductase to catalyse the synthesis of cholesterol, and inversely, high-level vitamin C inhibits the enzyme activity and lowers the rate of cholesterol production [42] .
There is now evidential data from observational studies, animal model studies, and laboratory studies on human cells linking vitamin C to the lowering of cholesterol, and that vitamin C acts as a "natural statin" ( Table 2 ). Naturally there would be high expectations in extrapolation to humans and the pressing need to carry out pilot studies and clinical trials to investigate the effect of high dose vitamin C on CHD. [43] . In CVD and CHD, much focus has been on the role of LDL. Lp(a) was discovered by Blumberg, Bernanke, and
Lipoprotein(a) and CHD
Allison [44] and by Berg [45] . Lp(a) and LDL share the same lipid and apoprotein composition, particularly apoprotein B-100 (apo B). But Lp(a) differs from LDL in that it has an additional glycoprotein, designated as apoprotein(a) [apo(a)]. In addition, Lp(a) has lysine-binding properties [46] . The level of Lp(a) in circulation depends primarily on its synthesis and, unlike LDL, is not determined by the efficacy of particle clearance [47] . Despite much progress made in understanding this lipoprotein particle, both the physiological role and the pathological mechanism of Lp(a) remain unclear [46] .
In 1987, the discovery of the structural homology between the two proteins, apo(a) and plasminogen [48] [49], and their DNA sequence [50] led to much interest in the research of Lp(a). The significance is that plasminogen is a key protein in the process of Postulated that rupture of intimal capillaries were due to pressure from hypertension, degeneration of tissues, and vitamin deficiency.
JC Paterson
Follow up study on coronary occlusion using microscopic examination of plaques.
Postulated that hypertension was a main factor for intimal capillary bleeding and plaque formation; and capillary fragility may be due to vitamin C deficiency.
GC Willis
Conducted experimental study on guinea pigs. Confirmed that atherosclerosis is linked to vitamin C deficiency.
The mechanical stress exerted onto the walls of arteries is link to the location of the atherosclerosis.
Serial angiography studies showed vitamin C could reduce atherosclerotic plaques in humans.
Contrary to common assumption, plaques could build up or be reversed fairly quickly. Plaques build up at points of mechanical stress in blood vessels.
Further studies showed that vitamin C could reverse atherosclerosis in guinea pigs.
1971
Constance Spittle
Studied the effect of vitamin C on healthy individuals and patients with atherosclerosis.
The transitory rise in serum cholesterol could be due to uprooting of cholesterol from the blood vessels.
1981
Holloway et al.
Observed that guinea pigs fed with a diet high in vitamin C could reduce cholesterol synthesis in the liver.
Simultaneously HMG CoA reductase was reduced.
1985
Green et al.
Studied the mechanism of vitamin C inhibition of HMG CoA reductase activity in guinea pig liver.
Study showed that vitamin C has an effect on reductase activity and cholesterol genesis.
1986
Harwood et al.
Advanced from animal model study to the study of human liver cells culture.
Low-level vitamin C triggered the HMG CoA reductase to catabolize cholesterol. High-level vitamin C reversed the effect.
The inverse relationship of Lp(a) to vitamin C, and the observations that Lp(a) molecules are primarily found in humans and in a few animal species (primates and fruit bats), led Matthias Rath, a German physician, to study vitamins and heart disease [55] .
Rath also observed that animals that are able to produce optimum amounts of vitamin fresh arterial wall tissues [56] . This cohort observational study showed significant positive correlation between serum Lp(a) and arterial wall apo(a). High serum Lp(a) also led to a significant increase of apo B in the arterial wall, but no significant correlation was found between apo B in serum and aortic tissue. Both apo(a) and apo B were found to be co-located in the arterial wall, predominantly located extracellularly. This study shows that Lp(a) accumulates in the arterial wall thereby contributing to plaque formation and CHD. A follow up study on autopsy tissues of aorta and left coronary artery (n = 74) confirmed the location of apo(a) in arterial intima, predominantly at the extracellular matrix [57] . Since apo(a) is a component of Lp(a), it was suggested, for the first time, that Lp(a) is an atherogenic particle. This differs from the finding of Smith and
Slater [10] as did findings of Rath et al. [56] . Apo(a) remains intact and stays in the ar- The study of Beisiegel, Niendorf [58] confirmed that Lp(a) contributes to plaque development by extracellular accumulation and only its minor amount is taken up in foam cells. More importantly this study suggested the mechanism that apo(a) might bind to fibrin and thereby inhibit the action of plasminogen. Apo(a) and fibrin are co-localized in the arterial wall and in the presence of Lp(a) will eventually become part of the plaque. Lp(a) can bind to the plasminogen receptor of endothelial cells [59] and enters the arterial intima via this pathway.
The Vitamin C-Heart Disease Connection: A New Concept
The Rath and Pauling presented a new concept of pathological mechanism for CVD.
CVD is primarily a degenerative disease and the primary cause is a deficiency in vitamin C which triggers impaired collagen synthesis thereby leading to the deposition of Lp(a) and fibrinogen/fibrin in the arterial wall [62] to compensate for its structural weakness. Rath and Pauling's new concept of pathological mechanism differs from those of Brown and Goldstein [63] , Ross [64] , and Steinberg, Parthasarathy [65] . It is also a wonder why Fortmann and Marcovina [46] did not consider Rath and Pauling's new concept which was published in 1991.
Rath and Pauling's pathological mechanism for CVD was extended further when they observed that apo(a) contains an amino acid sequence: arginine-glycine-aspartate (RGD) tripeptide, a characteristic sequence in adhesive proteins. RGD interacts with integrins, a family of cell receptors for adhesive proteins [66] . Rath and Pauling [67] suggested that apo(a) is an adhesive protein and physiologically it mediates cell adhesion and migration, as well as processes like cell differentiation and growth. Under pathological conditions, apo(a) which is a large protein comparable in size to collagen can compensate for vitamin C deficiency. When the collagen matrix is weak, apo(a) mediates in cellular and extracellular chronic repair processes. Apo(a) is involved in tissue repair processes such as would healing [68] .
In 1992, Rath and Pauling presented a unified theory of CVD [69] when at that time the therapeutic concepts for CVD were targeting specific risk factors or individual pathological mechanism. The theory is that vitamin C deficiency is an important underlying factor and that all mechanisms leading to CVD can be triggered by vitamin C deficiency. The study of the pathological mechanism in CVD led Rath to advance the concept further. He recognized that most chronic diseases proliferate via a similar pathological mechanism, and the most commonly held view is the one propagated by oxygen free radicals. Rath and Pauling [70] proposed another pathological mechanism:
the enzymatic degradation of the connective tissue by the protease, plasmin. In healthy fibrinogen/fibrin in the vascular wall [71] . Study using a mouse model, which is unable to produce endogenous vitamin C (Gulo-/-) have demonstrated structural changes in the vascular wall accompanied by elevated cholesterol levels triggered by ascorbate deficient diet [72] . In vitro study with vascular smooth muscle cells isolated from guinea-pig aorta investigated the direct and matrix-mediated effects of ascorbate on the proliferation rate of these cells. The results showed diminished cell proliferation in the presence of 0.5 -2 mM ascorbate, in a dose-dependent manner without cytotoxic effect [73] .
Additionally, a number of studies showed cardio-protective effects of other micronutrients, such as those contained in tea, through their potent antioxidant activity [74] Also, vitamin C, amino acid, lysine and proline, green tea extract, and quercetin, among others have shown to strengthen the integrity of ECM. Ivanov et al., have reported that a mixture of ascorbic acid, quercetin, green tea extract and gotu kola effectively reduce monocyte binding to the ECM thereby reducing atherosclerotic plaque buildup [75] .
Vitamins and CHD: Clinical Implications
In a pilot clinical study involving patients with elevated plasma Lp(a) levels, vitamin C was found to lower its levels in 9 out 11 patients on average by 27%, with a median value also of 27% [76] . On the basis of an improved understanding on the pathogenesis of CVD, Rath proceeded to define a new therapeutic approach for reducing the risk of CVD with nutritional supplements. The basis for this approach is that vitamin C is es- can function as a repair molecule accumulating at the sites of vessel wall damage (insufficient collagen production) during vitamin C deficiency.
Implications of Vitamin C-Lp(a)-CHD Connection
Currently accepted cholesterol-based theory of heart disease is not able to adequately answer the key questions in cardiology. The quantitative evaluation of histological immunostains for apo(a) and apoB-100 in the vascular wall is expressed as a score value calculated by multiplying the immunostained area by its intensity. The proximal, ascending, descending and thoracic part of the aorta was examined, including its branching vessels. Only areas in which apo(a) and apoB-100 were co-localized and formed clear deposits were included. A "O" score represents no deposits, "1" minimal deposit(s), "2" moderate deposit(s), and a score of "3" represents extensive deposit(s). The basis of this, Steinberg argued, proves the lipid hypothesis. However, several trials failed to prove the cholesterol lowering by statins resulted in reduction of myocardial infarction and cardiovascular events. Gaps and major questions that remain unanswered in the lipid hypothesis of atherosclerosis could be answered by Rath and Pauling concept [60] and their unified theory of human cardiovascular disease [69] . They explain that the weakening of the vascular collagen matrix at the sites of high hemodynamic stress, which happens at coronary arteries, is the causative risk factors of CVD. This eventually leads to the weakening of collagen matrix and expansion of endothelial gaps allowing for an influx of large molecules Lp(a) and LDL as repair factors for vascular wall. The most frequent cause of the weakening of the vascular wall structure is chronic deficiency of vitamin C and consequently inadequate collagen synthesis. Finally, the sequel of CHD, myocardial infarction, and heart failure become self-evident. Understanding this mechanism may guide the natural prevention of this disease and form the basis for developing effective therapeutic strategies aiming at natural reversal of atherosclerosis through the reinforcement of the vascular wall structure as its primary goal.
With the publication of the recent experimental study on the effects of vitamin C on Lp(a) in transgenic mice [77] , it now remains for clinical trials with more rigorous design to follow through.
